Latest News and Press Releases

Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage...

Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months)INB-100 continues...

Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being...

INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual...

Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML).Clinical activity observed includes continuing robust...

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...

Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studiesPotential to expand the agreement to support commercial-scale manufacturing ...

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...